ERBB2 and neoplasm: Our data revealed that treatment with either MM-121 or paclitaxel (7.5 mg/kg) had no significant effects on tumor cell morphology, tumor mass architecture, and the expression of erbB2/erbB3 receptors (Figure 5B).